<DOC>
	<DOCNO>NCT00078234</DOCNO>
	<brief_summary>The treatment combination Rituxan® ( rituximab ) fludarabine previously report produce high percentage response less toxicity combination treatment . However , leukemia subject continue leukemia despite treatment standard anticancer drug therapy , may work short period time . In subject , leukemia respond well therapy leukemia cell may over-producing one protein . One proteins call Bcl-2 . Bcl-2 protein appear protect cancer cell kill thus lengthens life cancer cell . Genasense® ( oblimersen sodium ) compound block production Bcl-2 protein . By first lowering level Bcl-2 , possible chemotherapy drug may work effectively cancer treatment . Genasense® may also directly kill CLL cell . This study test whether treat subject Genasense® , fludarabine rituximab safe effective .</brief_summary>
	<brief_title>Genasense® ( Oblimersen Sodium ) , Fludarabine , Rituximab Subjects With Chronic Lymphocytic Leukemia</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Vidarabine</mesh_term>
	<criteria>Key Absolute lymphocyte count &gt; 10,000 cells/mm3 history ALC &gt; 10,000 cell/mm3 Platelets &gt; 50,000 cells/mm3 Tumor lymphocytes express surface CD5 , CD19 , CD20 CD23 Creatinine &lt; 1.5 mg.dL Key Less 3 week prior major surgery therapy CLL include radiation therapy , chemotherapy , highdose steroid therapy , immunotherapy , cytokine , biologic vaccine therapy . History autoimmune hemolytic anemia Prior allogeneic transplant</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2009</verification_date>
	<keyword>CLL</keyword>
	<keyword>Leukemia</keyword>
	<keyword>Chronic</keyword>
	<keyword>Cancer</keyword>
	<keyword>Adult</keyword>
	<keyword>Lymphocytic</keyword>
	<keyword>Genasense</keyword>
	<keyword>G3139</keyword>
	<keyword>Genta</keyword>
	<keyword>Bcl-2</keyword>
	<keyword>Antisense</keyword>
	<keyword>Oligonucleotide</keyword>
	<keyword>oblimersen</keyword>
</DOC>